Lyka Labs Ltd
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
- Market Cap ₹ 359 Cr.
- Current Price ₹ 109
- High / Low ₹ 144 / 92.6
- Stock P/E
- Book Value ₹ 30.0
- Dividend Yield 0.00 %
- ROCE 2.69 %
- ROE -2.92 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
- Promoter holding has increased by 3.29% over last quarter.
Cons
- Company has low interest coverage ratio.
- Debtor days have increased from 68.4 to 88.3 days.
- Working capital days have increased from 47.9 days to 77.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
95 | 87 | 90 | 57 | 78 | 42 | 41 | 41 | 62 | 164 | 81 | 106 | |
82 | 88 | 72 | 49 | 56 | 42 | 40 | 44 | 48 | 67 | 65 | 92 | |
Operating Profit | 13 | -2 | 18 | 8 | 22 | -1 | 1 | -3 | 14 | 98 | 16 | 15 |
OPM % | 13% | -2% | 20% | 14% | 28% | -1% | 2% | -8% | 23% | 59% | 19% | 14% |
4 | 24 | 5 | 11 | -0 | 3 | 2 | -25 | 1 | -2 | -4 | 2 | |
Interest | 16 | 24 | 18 | 11 | 17 | 8 | 6 | 19 | 26 | 20 | 12 | 5 |
Depreciation | 3 | 5 | 4 | 3 | 6 | 6 | 4 | 8 | 8 | 15 | 14 | 12 |
Profit before tax | -3 | -7 | 1 | 5 | -1 | -11 | -7 | -55 | -18 | 60 | -13 | -1 |
Tax % | 0% | 0% | 0% | 0% | 66% | 3% | 124% | -0% | 21% | 34% | -1% | -143% |
-3 | -7 | 1 | 5 | -0 | -11 | 2 | -55 | -14 | 40 | -13 | -2 | |
EPS in Rs | -1.30 | -3.37 | 0.63 | 2.19 | -0.09 | -3.85 | 0.61 | -19.31 | -5.04 | 13.91 | -4.33 | -0.69 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 20% |
TTM: | 32% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 22% |
TTM: | 63% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 33% |
3 Years: | 16% |
1 Year: | 16% |
Return on Equity | |
---|---|
10 Years: | -6% |
5 Years: | -3% |
3 Years: | 22% |
Last Year: | -3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 |
Reserves | 45 | 40 | 38 | 43 | 52 | 68 | 70 | -10 | -24 | 16 | 28 | 66 |
Preference Capital | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
128 | 139 | 108 | 105 | 112 | 101 | 90 | 136 | 162 | 128 | 73 | 57 | |
52 | 62 | 66 | 58 | 57 | 48 | 60 | 66 | 47 | 36 | 47 | 29 | |
Total Liabilities | 247 | 263 | 233 | 228 | 243 | 245 | 249 | 221 | 213 | 209 | 179 | 186 |
95 | 94 | 62 | 60 | 86 | 81 | 76 | 102 | 95 | 90 | 66 | 57 | |
CWIP | 15 | 22 | 27 | 30 | 24 | 26 | 30 | 26 | 24 | 18 | 16 | 22 |
Investments | 20 | 63 | 63 | 63 | 62 | 62 | 62 | 32 | 32 | 32 | 32 | 32 |
116 | 84 | 82 | 75 | 70 | 75 | 80 | 61 | 61 | 68 | 65 | 75 | |
Total Assets | 247 | 263 | 233 | 228 | 243 | 245 | 249 | 221 | 213 | 209 | 179 | 186 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
14 | 55 | 29 | 8 | 20 | 7 | 18 | -11 | 6 | 77 | 7 | 3 | |
-10 | -25 | 30 | 5 | -5 | -3 | -3 | 0 | 0 | -4 | 7 | -9 | |
-1 | -29 | -63 | -13 | -15 | -4 | -16 | 20 | -8 | -63 | -20 | 3 | |
Net Cash Flow | 3 | 2 | -3 | 0 | -0 | -1 | -0 | 8 | -2 | 9 | -7 | -3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 229 | 107 | 116 | 169 | 113 | 265 | 263 | 59 | 58 | 39 | 78 | 88 |
Inventory Days | 94 | 58 | 90 | 74 | 93 | 124 | 98 | 99 | 67 | 97 | 87 | 81 |
Days Payable | 243 | 235 | 283 | 323 | 283 | 536 | 519 | 430 | 301 | 109 | 103 | 93 |
Cash Conversion Cycle | 80 | -70 | -77 | -80 | -76 | -147 | -159 | -272 | -176 | 26 | 62 | 77 |
Working Capital Days | 105 | -153 | -167 | -196 | -222 | -456 | -62 | -201 | -90 | 11 | 55 | 78 |
ROCE % | 7% | -1% | 9% | 9% | 10% | -3% | -0% | -5% | 5% | 50% | 4% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23 May - Enclosed standalone and consolidated financial results as published in the newspapers under Regulation 47 of the SEBI (LODR) Regulations, 2015.
- Financial Results For The Year Ended 31.03.2024 21 May
- Board Meeting Outcome for Outcome Of Board Meeting 21 May
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 15 May
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 15 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
-
Financial Year 2009
from bse
Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.